MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia
Rafael Holdings, Inc. Class B (RFL)
NASDAQ:AMEX Investor Relations:
morningstar.com/funds/xnas/rytnx/quote.html
Company Research
Source: GlobeNewswire
Cranbury, NJ, April 28, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the expansion of its Phase 2 clinical trial of CPI-613® (devimistat) for patients with relapsed or refractory Burkitt’s lymphoma/leukemia. The clinical trial will begin enrolling patients at MD Anderson Cancer Center, where Dr. Raphael Steiner will serve as principal investigator. The trial is led by Ariela Noy, M.D., at Memorial Sloan Kettering Cancer Center in New York City. Patients can also enroll at City of Hope in Duarte, California and at Massachusetts General Hospital in Boston. “We are happy to expand access to our clinical trial for patients with Burkitt’s lymphoma, especially through the highly prestigious institution of MD Anderson, alongside the other world-renowned sites for this trial,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. “Our mission at Rafael
Show less
Read more
Impact Snapshot
Event Time:
RFL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RFL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RFL alerts
High impacting Rafael Holdings, Inc. Class B news events
Weekly update
A roundup of the hottest topics
RFL
News
- Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial ResultsGlobeNewswire
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTXAccesswire
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTXAccesswire
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTXAccesswire
RFL
Sec Filings
- 11/19/24 - Form DEF
- 11/7/24 - Form 10-K
- 11/7/24 - Form 8-K
- RFL's page on the SEC website